CervoMed (CRVO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in June 2024; topline data expected in December 2024 - - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod's potential for patients with early-stage DLB – - Completed private placement for up to $149.4 million of potential proceeds w ...